Mero-84Homo sapiens (Human)Cancer cell line
Also known as: MERO84
🤖 AI SummaryBased on 2 publications
Quick Overview
Human malignant mesothelioma cell line for cancer research.
Detailed Summary
Mero-84 is a human malignant mesothelioma cell line established from tumor samples. It exhibits abnormal karyotypes and expresses epithelial membrane antigen (EMA). The cell line shows variable doubling times and does not undergo senescence. Cytogenetic analysis indicates chromosomal abnormalities, and it is used in studies of mesothelioma biology and therapeutic development. Mero-84 is also implicated in Hippo pathway research due to mutations in genes like NF2 and LATS2, highlighting its relevance in understanding tumor progression and potential targeted therapies.
Research Applications
Cancer researchMesothelioma biologyTherapeutic developmentHippo pathway studies
Key Characteristics
Abnormal karyotypesEMA expressionVariable doubling timesNo senescenceChromosomal abnormalities
Generated on 6/19/2025
Basic Information
| Database ID | CVCL_2596 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age Category | Unknown |
|---|---|
| Sex | Male |
Disease Information
| Disease | Pleural mesothelioma |
|---|---|
| Lineage | Pleura |
| Subtype | Pleural Mesothelioma, Biphasic Type |
| OncoTree Code | PLBMESO |
DepMap Information
| Source Type | Sigma-Aldrich |
|---|---|
| Source ID | ACH-001561_source |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Amelogenin
X
CSF1PO
10,11
D13S317
8,12
D16S539
9
D18S51
15,16
D21S11
29,31,32
D3S1358
16
D5S818
11
D7S820
9,11
D8S1179
12
FGA
19
Penta D
10,13
Penta E
7,11
TH01
9
TPOX
9,11
vWA
14,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines
Loading gene expression data...
Publications
Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Asamura H., Gemma A., Yamada T.
J. Thorac. Oncol. 10:844-851(2015).